Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer.

ABSTRACT:

Background

Everolimus was the first orally targeted therapy for certain cancers. It was introduced before CDK4/6 inhibitors and is widely used to treat advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This study presents comprehensive findings including updated data and long-term survival analyses focusing on patients with HR+/HER2- metastatic breast cancer who received everolimus-based treatment. The objectives were to assess the impact of everolimus on overall survival (OS) and progression-free survival (PFS) by treatment line, and to evaluate its role in therapeutic strategies in a real-world setting.

Methods

We included 299 women aged over 20 years with histologically confirmed HR+/HER2- breast cancer who r

SUBMITTER: Kao YC 

PROVIDER: S-EPMC12718841 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature